EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis.
Max Yates,Max Yates,Richard A. Watts,Ingeborg M. Bajema,Maria C. Cid,Bruno Crestani,Thomas H. Hauser,Bernhard Hellmich,Julia U Holle,Martin Laudien,Mark A. Little,Raashid Luqmani,Alfred Mahr,Peter A. Merkel,John Mills,Janice Mooney,Mårten Segelmark,Vladimir Tesar,Kerstin Westman,Augusto Vaglio,Nilüfer Yalçındağ,David Jayne,Chetan Mukhtyar +22 more
TLDR
The 2009 European League Against Rheumatism recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated and 15 recommendations were developed, covering general aspects, such as attaining remission.Abstract:
In this article, the 2009 European League Against Rheumatism (EULAR) recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) have been updated. The 2009 recommendations were on the management of primary small and medium vessel vasculitis. The 2015 update has been developed by an international task force representing EULAR, the European Renal Association and the European Vasculitis Society (EUVAS). The recommendations are based upon evidence from systematic literature reviews, as well as expert opinion where appropriate. The evidence presented was discussed and summarised by the experts in the course of a consensus-finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) determined. In addition to the voting by the task force members, the relevance of the recommendations was assessed by an online voting survey among members of EUVAS. Fifteen recommendations were developed, covering general aspects, such as attaining remission and the need for shared decision making between clinicians and patients. More specific items relate to starting immunosuppressive therapy in combination with glucocorticoids to induce remission, followed by a period of remission maintenance; for remission induction in life-threatening or organ-threatening AAV, cyclophosphamide and rituximab are considered to have similar efficacy; plasma exchange which is recommended, where licensed, in the setting of rapidly progressive renal failure or severe diffuse pulmonary haemorrhage. These recommendations are intended for use by healthcare professionals, doctors in specialist training, medical students, pharmaceutical industries and drug regulatory organisations.read more
Citations
More filters
Journal ArticleDOI
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
Joseph E. Schwartz,Jeffrey L. Winters,Anand Padmanabhan,Rasheed A. Balogun,Meghan Delaney,Michael L. Linenberger,Zbigniew M. Szczepiorkowski,Mark E. Williams,Yanyun Wu,Beth H. Shaz +9 more
TL;DR: The Eighth Edition of the JCA Special Issue seeks to continue to serve as a key resource that guides the utilization of TA in the treatment of human disease.
Journal ArticleDOI
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Michael E. Wechsler,Praveen Akuthota,David Jayne,Paneez Khoury,Amy D. Klion,Carol A. Langford,Peter A. Merkel,Frank Moosig,Ulrich Specks,Maria C. Cid,Raashid Luqmani,Judith Brown,Stephen Mallett,Richard Philipson,Steve Yancey,Jonathan Steinfeld,Peter F. Weller,Gerald J. Gleich +17 more
TL;DR: In participants with eosinophilic granulomatosis with polyangiitis, mepolizumab resulted in significantly more weeks in remission and a higher proportion of participants in remission than did placebo, thus allowing for reduced glucocorticoid use.
Journal ArticleDOI
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Brad H. Rovin,Sharon G. Adler,Jonathan Barratt,Frank Bridoux,Kelly A. Burdge,Tak Mao Chan,H. Terence Cook,Fernando C. Fervenza,Keisha L. Gibson,Richard J. Glassock,David Jayne,Vivekanand Jha,Adrian Liew,Zhihong Liu,Juan M. Mejia-Vilet,Carla M. Nester,Jai Radhakrishnan,Elizabeth M. Rave,Heather N. Reich,Pierre Ronco,Jan-Stephan F. Sanders,Sanjeev Sethi,Yusuke Suzuki,Sydney C.W. Tang,Vladimir Tesar,Marina Vivarelli,Jack F.M. Wetzels,Jürgen Floege +27 more
Journal ArticleDOI
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
David Jayne,Annette Bruchfeld,Lorraine Harper,Matthias Schaier,Michael Venning,Patrick B. Hamilton,Volker Burst,Franziska Grundmann,Michel Jadoul,Istvan Szombati,Vladimír Tesař,Mårten Segelmark,Antonia Potarca,Thomas J. Schall,Pirow Bekker +14 more
TL;DR: In conclusion, C5a receptor inhibition with avacopan was effective in replacing high-dose glucocorticoids in treating vasculitis.
Journal ArticleDOI
Pathogenesis and therapeutic interventions for ANCA-associated vasculitis
TL;DR: Advances in the understanding of anti-neutrophil cytoplasmic antibody-associated vasculitis are described and promising new treatments that target B cells, T cells and cytokines are generated; potential novel approaches targeting additional cells or molecules are also discussed.
References
More filters
Journal ArticleDOI
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
John Charles Jennette,Ronald Falk,P. A. Bacon,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gary S. Hoffman,David Jayne,Cees G. M. Kallenberg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,Alfred Mahr,Eric L. Matteson,Peter A. Merkel,Peter A. Merkel,Seza Ozen,Charles D. Pusey,Niels Rasmussen,Andrew J. Rees,David G. I. Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +28 more
TL;DR: 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides J. Watts; Arthritis & Rheumatism
2012 Revised International Chapel Hill Consensus Conference Nomenclature of
John Charles Jennette,Ronald Falk,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Peter Lamprecht,Raashid Luqmani,Seza Ozen,Andrew J. Rees,Scott Dgi,Ulrich Specks,Kei Takahashi,Richard A. Watts +16 more
TL;DR: In this article, the running head is assigned to one of the following candidates:Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, Ferrardo F, Flores-Suarez LF, Gross WL, Guillevin L, Hagen EC, Hoffman GS, Jayne DR, Kallenberg CGM, Lamprecht P, Langford CA, Luqmani RA, Mahr AD, Matteson EL, Merkel PA, Ozen S, Pusey CD, Rasmussen N, Rees
Journal ArticleDOI
Wegener granulomatosis : an analysis of 158 patients
Gary S. Hoffman,Gail S. Kerr,Randi Y. Leavitt,Claire W. Hallahan,Robert S. Lebovics,William D. Travis,Menachem Rottem,Anthony S. Fauci +7 more
TL;DR: The course of Wegener granulomatosis has been dramatically improved by daily treatment with cyclophosphamide and glucocorticoids, and has led to increasing concerns about toxicity resulting from prolonged cycloph phosphamide therapy and has encouraged investigation of other therapeutic regimens.
Journal ArticleDOI
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
TL;DR: Rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
Journal ArticleDOI
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
Rachel B Jones,Jan Willem Cohen Tervaert,Thomas H. Hauser,Raashid Luqmani,Matthew D. Morgan,Chen Au Peh,Caroline O. S. Savage,Mårten Segelmark,Vladimir Tesar,Pieter van Paassen,D Walsh,Michael Walsh,Kerstin Westman,David Jayne +13 more
TL;DR: A rituximab-based regimen was not superior to standard intravenous cyclophosphamide for severe ANCA-associated vasculitis and was not associated with reductions in early severe adverse events.
Related Papers (5)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
John Charles Jennette,Ronald Falk,P. A. Bacon,Neil Basu,Maria C. Cid,Franco Ferrario,Luis Felipe Flores-Suárez,W. L. Gross,Loïc Guillevin,E. C. Hagen,Gary S. Hoffman,David Jayne,Cees G. M. Kallenberg,Peter Lamprecht,Carol A. Langford,Raashid Luqmani,Alfred Mahr,Eric L. Matteson,Peter A. Merkel,Peter A. Merkel,Seza Ozen,Charles D. Pusey,Niels Rasmussen,Andrew J. Rees,David G. I. Scott,Ulrich Specks,John H. Stone,Kei Takahashi,Richard A. Watts +28 more
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
John H. Stone,Peter A. Merkel,Robert Spiera,Philip Seo,Carol A. Langford,Gary S. Hoffman,Cees G. M. Kallenberg,E. William St. Clair,Anthony M. Turkiewicz,Nadia K. Tchao,Lisa Webber,Linna Ding,Lourdes P. Sejismundo,Kathleen Mieras,David Weitzenkamp,David Ikle,Vicki Seyfert-Margolis,Mark Mueller,Paul Brunetta,Nancy B. Allen,Fernando C. Fervenza,Duvuru Geetha,Karina A. Keogh,Eugene Y. Kissin,Paul A. Monach,Tobias Peikert,Coen A. Stegeman,Steven R. Ytterberg,Ulrich Specks +28 more
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
Loïc Guillevin,Christian Pagnoux,Alexandre Karras,Chahéra Khouatra,Olivier Aumaître,Pascal Cohen,François Maurier,Olivier Decaux,Jacques Ninet,P. Gobert,Thomas Quemeneur,Claire Blanchard-Delaunay,Pascal Godmer,Xavier Puéchal,Pierre-Louis Carron,Pierre-Yves Hatron,Nicolas Limal,Mohamed Hamidou,Maize Ducret,Eric Daugas,Thomas Papo,Bernard Bonnotte,Alfred Mahr,Philippe Ravaud,Luc Mouthon +24 more